Extended indication Adult Participants With unexplained Chronic Cough
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Gefapixant
Domain Lung diseases
Reason of inclusion New medicine (specialité)
Main indication Other lung
Extended indication Adult Participants With unexplained Chronic Cough
Manufacturer MSD
Mechanism of action Receptor antagonist
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Submission date 2021
Expected Registration 2022
Orphan drug No
Registration phase Clinical trials
Additional comments Datum indiening en verwachte registratie is op basis van estimated primary completion June 2020.

Therapeutic value

Current treatment options hoestprikkeldempende middelen (codeïne)
Therapeutic value No judgement
Duration of treatment continuous
Frequency of administration 2 times a day
Dosage per administration 45mg tot 50mg
References NCT03449134

Expected patient volume per year

References Morice A. Chronic cough: epidemiology. Chron Respir Dis. 2008;5(1):43-7.
Additional comments Onder chronisch hoesten wordt verstaan dat het hoesten meer dan 8 weken aanhoudt. De prevalentie in de algemene bevolking wordt geschat op 12%. De drie voornaamste oorzaken van chronisch hoesten bij een niet-roker met een normale thoraxradiografie zijn astma, gastro-intestinale reflux (GER) en rhinosinusitis. Voor een aanzienlijk aantal patiënten kan er echter geen oorzaak gevonden worden en is er sprake van chronische idiopatische hoest.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.